A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors

被引：6
|
作者：
Bonomi, M. [1 ]
Bhateja, P. [1 ]
Issa, M. [1 ]
Klamer, B. [2 ]
Pan, X. [2 ]
Blakaj, A. [3 ]
Karivedu, V [1 ]
Mousa, L. [1 ]
Mitchell, D. [5 ]
Gamez, M. [5 ]
Kang, S. [4 ]
Seim, Nolan B. [4 ]
Old, M. [4 ]
Carrau, R. [4 ]
Rocco, J. [4 ]
Blakaj, D. [5 ]
机构：
[1] Ohio State Univ, Div Med Oncol, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
[3] Yale Univ, Div Radiat Oncol, New Haven, CT USA
[4] Ohio State Univ, Div Otolaryngol, Columbus, OH 43210 USA
[5] Ohio State Univ, Div Radiat Oncol, Columbus, OH 43210 USA
来源：
ORAL ONCOLOGY | 2020年 / 110卷
关键词：
PD-1; inhibitors; Metastatic; Head and neck cancer; Response; Predictors; Immunotherapy; CANCER; IMMUNOTHERAPY; NIVOLUMAB; RECURRENT; INDEX;
D O I：
10.1016/j.oraloncology.2020.104900
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: ICIs have expanded treatment options for HNSCC. A minority of the patients respond to these expensive treatments. Patients and methods: This is a single institutional retrospective review on 121 unresectable or metastatic HNSCC patients treated with ICIs. We predicted that inflammatory markers available through routine blood work, in addition to clinical characteristics may divide patients into groups more or less likely to respond to these agents. Here we develop and internally validate our nomogram to predict survival in patients treated with ICIs.
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Brain metastasis in head and neck squamous cell carcinoma after immune check point inhibitors treatment
    Lorini, Luigi
    Merlano, Marco
    Licitra, Lisa
    Ravanelli, Marco
    Bossi, Paolo
    ORAL ONCOLOGY, 2021, 116
  • [2] Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort
    Majd Issa
    Brett G. Klamer
    Nikol Mladkova
    Georgios I. Laliotis
    Vidhya Karivedu
    Priyanka Bhateja
    Chase Byington
    Khaled Dibs
    Xueliang Pan
    Arnab Chakravarti
    John Grecula
    Sachin R. Jhawar
    Darrion Mitchell
    Sujith Baliga
    Matthew Old
    Ricardo L. Carrau
    James W. Rocco
    Dukagjin M. Blakaj
    Marcelo Bonomi
    BMC Cancer, 22
  • [3] Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort
    Issa, Majd
    Klamer, Brett G.
    Mladkova, Nikol
    Laliotis, Georgios I.
    Karivedu, Vidhya
    Bhateja, Priyanka
    Byington, Chase
    Dibs, Khaled
    Pan, Xueliang
    Chakravarti, Arnab
    Grecula, John
    Jhawar, Sachin R.
    Mitchell, Darrion
    Baliga, Sujith
    Old, Matthew
    Carrau, Ricardo L.
    Rocco, James W.
    Blakaj, Dukagjin M.
    Bonomi, Marcelo
    BMC CANCER, 2022, 22 (01)
  • [4] Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
    Arribas, Lorena
    Plana, Maria
    Taberna, Miren
    Sospedra, Maria
    Vilarino, Noelia
    Oliva, Marc
    Pallares, Natalia
    Gonzalez Tampan, Ana Regina
    Miguel Del Rio, Luis
    Mesia, Ricard
    Baracos, Vickie
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Immune Checkpoint Inhibitors for Head and Neck Squamous Cell Carcinoma
    Chang, Hui-Chin
    Gau, Shuo-Yan
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2025, 151 (02)
  • [6] DNA methylation profiling in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
    Starzer, Angelika Martina
    Heller, Gerwin
    Tomasich, Erwin
    Feldmann, Katharina
    Hatziioannou, Teresa
    Traint, Stefan
    Minichsdorfer, Christoph
    Schwarz-Nemec, Ursula
    Nackenhorst, Maja
    Muellauer, Leonhard
    Preusser, Matthias
    Berghoff, Anna Sophie
    Fuereder, Thorsten
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Prognostic significance of nutritional indices in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors
    Miyamoto, Noriyuki
    Takenaka, Yukinori
    Sudo, Takato
    Eguchi, Hirotaka
    Tanaka, Hidenori
    Fukusumi, Takahito
    Takemoto, Norihiko
    Suzuki, Motoyuki
    Inohara, Hidenori
    ACTA OTO-LARYNGOLOGICA, 2023, 143 (10) : 925 - 930
  • [8] Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma
    Zhang, Xue-Mei
    Song, Ling-Jun
    Shen, Juan
    Yue, Hao
    Han, Ya-Qin
    Yang, Chen-Ling
    Liu, Shi-Yun
    Deng, Jia-Wen
    Jiang, Yue
    Fu, Guo-Hui
    Shen, Wei-Wei
    HUMAN PATHOLOGY, 2018, 82 : 104 - 112
  • [9] Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).
    Alfieri, Salvatore
    Ferrara, Roberto
    Calareso, Giuseppina
    Cavalieri, Stefano
    Platini, Francesca
    Mancinelli, Moela
    Resteghini, Carlo
    Orlandi, Ester
    Iacovelli, Nicola Alessandro
    Ferella, Letizia
    Piazza, Cesare
    Apollonio, Giulia
    Galbiati, Donata
    Bossi, Paolo
    Bergamini, Cristiana
    Locati, Laura Deborah
    Licitra, Lisa F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Prognostic and predictive value of skeletal muscle mass (SMM) in squamous cell carcinoma of the head and neck (SCCHN) in patients treated with immune checkpoint inhibitors (ICI)
    Arribas, L.
    Plana, M.
    Sospedra, M.
    Vilarino, N.
    Taberna Sanz, M.
    Mesia Nin, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S675 - S675
12345